Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. APGE
6. MU
7. DFTX
8. LCO
9. KR
10. MSTR

Go back to Natera Enrolls First Patients in SIGNAL-ER 101, a Prospective, Interventional Study Evaluating MRD-Guided Therapy in Breast Cancer
(NASDAQ: NTRA) Delayed: 224.44 -6.97 (3.01%)
Previous Close $231.41    52 Week High $13.80 
Open $231.52    52 Week Low $6.52 
Day High $234.14    P/E N/A 
Day Low $219.50    EPS $0.00 
Volume 642,056